Titan Medical to Participate in Upcoming Investor Conferences
Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD)
(Nasdaq: TMDI), a medical device company focused on the design and
development of surgical technologies for robotic single access
surgery, today announced that, David McNally, President, CEO and
Chairman and Monique Delorme, CFO of Titan Medical, will
participate in two upcoming virtual investor conferences.
On March 16, 2021, Titan Medical will lead a day of one-on-one
meetings with investors at the 33rd Annual ROTH Conference.
On March 17, 2021 at 2:30 p.m. ET, Titan Medical will
participate in a fireside chat providing an overview of the Company
and its Enos™ robotic single access surgical system at the
Oppenheimer 31st Annual Healthcare Conference. A link to the live
discussion and the replay will be available on the Company’s
website www.titanmedicalinc.com under the “Investors” section. The
conference also includes a day of one-on-one meetings with
About Titan Medical
Titan Medical Inc., a medical device company headquartered in
Toronto, is focused on developing robotic assisted technologies for
application in single access surgery. The Enos system, by Titan
Medical, is being developed with dual 3D and 2D high-definition
vision systems, multi-articulating instruments, and an ergonomic
surgeon workstation. With the Enos system, Titan intends to
initially pursue gynecologic surgical indications.
Certain of Titan’s robotic assisted surgical technologies and
related intellectual property have been licensed to Medtronic plc,
while retaining world-wide rights to commercialize the technologies
for use with the Enos system.
Enos™ is a trademark of Titan Medical Inc.
For more information, visit www.titanmedicalinc.com.
This news release contains “forward-looking statements” within
the meaning of applicable Canadian and U.S. securities laws, which
reflect the current expectations of management of the Company’s
future growth, results of operations, performance, and business
prospects and opportunities. Wherever possible, words such as
“may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”,
“expect”, “intend”, “estimate”, “potential for” and similar
expressions have been used to identify these forward-looking
statements. These statements reflect management’s current beliefs,
and are based on information currently available to management.
Forward-looking statements involve significant risks, uncertainties
and assumptions. Many factors could cause actual results,
performance or achievements to be materially different from any
future results, performance or achievements that may be expressed
or implied by such forward-looking statements, including, without
limitation, those listed in the “Risk Factors” section of the
Company’s Annual Report on Form 20-F for the fiscal year ended
December 31, 2019 and the Company’s 2020 annual management’s
discussion and analysis (which may be viewed at www.sedar.com and
at www.sec.gov). Should one or more of these risks or uncertainties
materialize, or should assumptions underlying the forward-looking
statements prove incorrect, actual results, performance, or
achievements may vary materially from those expressed or implied by
the forward-looking statements contained in this news release.
These factors should be considered carefully, and prospective
investors should not place undue reliance on the forward-looking
statements. Although the forward-looking statements contained in
the news release are based upon what management currently believes
to be reasonable assumptions, the Company cannot assure prospective
investors that actual results, performance or achievements will be
consistent with these forward-looking statements. Except as
required by law, the Company expressly disclaims any intention or
obligation to update or revise any forward-looking statements
whether as a result of new information, future events or
version on businesswire.com: https://www.businesswire.com/news/home/20210310005324/en/
Monique L. Delorme Chief Financial Officer +1-416-548-7522